Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: Results of a 1-year controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 5, 2004, Pages 563-570

  Pereira, S P ^a,b,c   O'Donohue, J ^a   Moniz, C ^a   Phillips, M G ^a   Abraha, H ^a   Buxton Thomas, M ^a   Williams, R ^a,b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCICHEW D3; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; ESTRACOMBI; ESTRADERM TTS 50; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; URSODEOXYCHOLIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; BLEEDING; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CALCIUM EXCRETION; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EFFECT; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HORMONE SUBSTITUTION; HUMAN; LUMBAR SPINE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINE LEVEL;

ADMINISTRATION, CUTANEOUS; AGED; AMINO ACIDS; BONE DENSITY; BONE REMODELING; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 1642286716     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01890.x     Document Type: Article

References (46)

1. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
2. Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1993; 327: 620-7.
3. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265-9.
4. Chow J, Tobias JH, Colston KW, Chamber TJ. Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Invest 1992; 89: 74-8.
5. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993; 341: 801-5.
6. Eastell R, Dickson ER, Hodgson SF, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991; 14: 296-300.
7. Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89: 47-50.
8. Guattery JM, Faloon WW. Effect of estradiol upon serum enzymes in primary biliary cirrhosis. Hepatology 1987; 7: 737-42.
9. van Erpecum KJ, van Berge Henegouwen GP, Verschoor L, Stoelwinder B, Willekens FL. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100: 482-8.
10. Uhler ML, Marks JW, Voigt BJ, Judd HL. Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J Clin Endocrinol Metab 1998; 83: 410-4.
11. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
12. Portmann B, Popper H, Neuberger J, Williams R. Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients. Gastroenterology 1985; 88: 1777-90.
13. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1-7.
14. Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 1992; 102: 310-3.
15. World Health Organization. Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Technical Report No. 843. Geneva: World Health Organization, 1994.
16. Li F, Pitt PI, Sherwood R, et al. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 1993; 23: 566-71.
17. Power MJ, Fottrell PF. Solid-phase enzymoimmunoassay for osteocalcin in human serum or plasma, with use of a monoclonal antibody. Clin Chem 1989; 35: 2087-92.
18. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108: 276-83.
19. Rosen H. Primary biliary cirrhosis and bone disease. Hepatology 1995; 21: 253-5.
20. Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103: 855-60.
21. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987; 7: 137-42.
22. Pereira SP, Bray GP, Pitt PI, Li F, Moniz C, Williams R. Non-invasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 323-8.
23. Stellon AJ, Webb A, Compston J, Williams R. Lack of osteomalacia in chronic cholestatic liver disease. Bone 1986; 7: 181-5.
24. Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988; 95: 787-92.
25. Diamond T, Stiel D, Mason R, et al. Serum vitamin D metabolites are not responsible for low turnover osteoporosis in chronic liver disease. J Clin Endocrinol Metab 1989; 69: 1234-9.
26. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-23.
27. Solerio E, Isaia G, Innarella R, et al. Osteoporosis: still a typical complication of primary biliary cirrhosis? Dig Liver Dis 2003; 35: 339-46.
28. Bagur A, Mautalen C, Findor J, Sorda J, Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int 1998; 63: 385-90.
29. Le Gars L, Grandpierre C, Chazouilleres O, Berenbaum F, Poupon R. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine 2002; 69: 195-200.
30. Ormarsdottir S, Ljunggren O, Mallmin H, Brahm H, Loof L. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 1999; 31: 84-90.
31. Springer JE, Cole DE, Rubin LA, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000; 118: 145-51.
32. Pares A, Guanabens N, Alvarez L, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001; 33: 554-60.
33. Verma A, Maxwell JD, Ang L, et al. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis. Osteoporos Int 2002; 13: 677-82.
34. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21: 389-92.
35. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991; 325: 1189-95.
36. Ajdukiewicz AB, Agnew JE, Byers PD, Wills MR, Sherlock S. The relief of bone pain in primary biliary cirrhosis with calcium infusions. Gut 1974; 15: 788-93.
37. Camisasca M, Crosignani A, Battezzati PM, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20: 633-7.
38. Olsson R, Mattsson LA, Obrant K, Mellstrom D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999; 19: 188-92.
39. Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 889-92.
40. O'Donohue J, Williams R. Hormone replacement therapy in women with liver disease. Br J Obstet Gynaecol 1997; 104: 1-3.
41. Naessen T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990; 113: 95-103.
42. Pors Nielsen S, Barenholdt O, Hermansen F, Munk-Jensen N. Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment. Br J Obstet Gynaecol 1994; 101: 319-24.
43. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. J Am Med Assoc 1996; 276: 1389-96.
44. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996; 312: 1254-9.
45. Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. Eur J Gastroenterol Hepatol 1999; 11: 817-20.
46. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50(Suppl. 1): i1-9.